These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10491737)

  • 1. The calcium receptor and calcimimetics.
    Wada M; Nagano N; Nemeth EF
    Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
    Nagano N; Nemeth EF
    J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of uremic bone disease using calcimimetic compounds.
    Olgaard K; Lewin E
    Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
    Negri AL; Slatopolsky EA
    Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcimimetics with potent and selective activity on the parathyroid calcium receptor.
    Nemeth EF; Steffey ME; Hammerland LG; Hung BC; Van Wagenen BC; DelMar EG; Balandrin MF
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):4040-5. PubMed ID: 9520489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future role of calcimimetics in end-stage renal disease.
    Goodman WG; Turner SA
    Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcimimetics: therapeutic potential in hyperparathyroidism.
    Cohen A; Silverberg SJ
    Curr Opin Pharmacol; 2002 Dec; 2(6):734-9. PubMed ID: 12482739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcimimetic agents and the calcium-sensing receptor.
    Coburn JW; Maung HM
    Curr Opin Nephrol Hypertens; 2000 Mar; 9(2):123-32. PubMed ID: 10757216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
    Rybczyńska A; Hoppe A
    Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcimimetics in the treatment of primary hyperparathyroidism.
    Antoniucci DM; Shoback D
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N141-5. PubMed ID: 12412791
    [No Abstract]   [Full Text] [Related]  

  • 15. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
    Lindberg JS
    Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
    Drüeke TB
    Nephrol Dial Transplant; 2002; 17 Suppl 11():20-2. PubMed ID: 12386252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcimimetic agents: review and perspectives.
    Ureña P; Frazão JM
    Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.
    Antonsen JE; Sherrard DJ; Andress DL
    Kidney Int; 1998 Jan; 53(1):223-7. PubMed ID: 9453023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.
    Chin JI; Miller SC; Wada M; Nagano N; Nemeth EF; Fox J
    J Am Soc Nephrol; 2000 May; 11(5):903-911. PubMed ID: 10770968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.